Harnessing AI in Healthcare: A Unique Opportunity for Diabetes Treatment in India

By Sumona Bose

January 11, 2024

The Rising Burden of Diabetes in India: A Unique Opportunity for AI

India’s escalating diabetes cases present a unique challenge, but also a unique opportunity. The vast amount of data available could be harnessed through electronic medical records, positioning India at the forefront of research in this area. The application of artificial intelligence (AI) and machine learning (ML) could provide valuable insights and help devise bespoke solutions.

Figure 1: Indian Map showing the distribution of Diabetes

 

AI and ML: A Game Changer in Chronic Disease Management

AI and ML are already making strides in chronic disease management, particularly diabetes. These technologies are being used to predict diabetes risk based on genomic data, diagnose diabetes using EHR data, and predict complications such as nephropathy and retinopathy. Google’s AI research unit, in collaboration with several Indian ophthalmology centres, has made significant advances in automated diagnosis and grading of diabetic retinopathy based on fundus photographs. The adoption of these technologies could dramatically increase the detection and early treatment of diabetic complications.

The Potential of AI and ML in India’s Healthcare System

The potential of AI and ML is particularly significant in India, where diabetes prevalence is estimated at 8-10%, with a slightly lower burden in rural areas compared to urban areas. However, the prevalence of diabetes in Delhi is estimated at around 27%, with 46% or more of the population having prediabetes. Such an early and extensive occurrence of diabetes could place a significant burden on the healthcare system.

AI and ML are only as good as the data used to generate this intelligence. India is sometimes referred to as a “country with no records”, highlighting the general lack of record-keeping as an essential part of medical practice. However, this burden of disease could be transformed into an opportunity if all data is harnessed in a usable form and AI and ML are used to generate insights and solutions specific to our population. A concerted and collective effort is needed by the government and large associations, like the Endocrine Society of India, to initiate data collections and research.

In conclusion, AI’s evolution in healthcare, particularly in the management of diabetes, offers a unique opportunity for India. With the right strategies and collaborations, AI could significantly improve the country’s healthcare system and contribute to better patient outcomes.

Reference url

Recent Posts

cemdisiran gMG treatment
Breakthrough in cemdisiran gMG treatment Advances Regulatory Landscape

By João L. Carapinha

June 25, 2026

Cemdisiran gMG treatment has cleared a critical hurdle after the FDA and EMA accepted Regeneron’s regulatory submissions for review in anti-AChR antibody-positive generalized myasthenia gravis (gMG). The investigational siRNA therapy targeting complement protein C5 could become the first subcutan...
Trodelvy ADC approval
Advancements in Breast Cancer Treatment Following Trodelvy ADC Approval

By João L. Carapinha

June 25, 2026

The Trodelvy ADC approval by the European Commission delivers the first antibody-drug conjugate approved for first-line use in adults with unresectable or metastatic triple-negative breast cancer who are ineligible for PD-1 or PD-L1 inhibitors. This
Cemiplimab Cervical Cancer Access
Cemiplimab Cervical Cancer Access Navigating Treatment and Value

By João L. Carapinha

June 24, 2026

Cemiplimab Cervical Cancer Access has been endorsed by NICE for adults with recurrent or metastatic cervical cancer that has progressed after platinum-based chemotherapy, provided patients have not previously received immunotherapy. The final draft guidance confirms that this PD-1 inhibitor deliv...